Internal Medicine, Hematology & Oncology · Wayne, NJ
NPI
1982688925
Since 2005
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
2
Medicare group memberships
Hospitals
2
Hospital affiliations
468 Parish Dr, Suite 4
Wayne, NJ, 07470
Phone (973) 694-5005
Groups this clinician bills Medicare through
Medicare paid, 2024
$1.7M
135,774 services
Medicare patients, 2024
263
Average age 77
Drug cost, 2024
$3.6M
700 prescriptions
Company payments, 2025
$1,938
From 25 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Vijaykumar Roy was code J1439 (injection, ferric carboxymaltose, 1 mg), 48,000 times for 19 patients. In total Vijaykumar Roy billed 135,774 services in 75 codes, and Medicare paid $1.7M.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2025-04-01.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J1439 Injection, ferric carboxymaltose, 1 mg | Office | 48,000 | 19 | $0.87 | $42K |
| Q5106 Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units | Office | 14,640 | 31 | $5.75 | $84K |
| J2916 Injection, sodium ferric gluconate complex in sucrose injection, 12.5 mg | Office | 1,981 | 25 | $1.71 | $3,382 |
| J2469 Injection, palonosetron hcl, 25 mcg | Office | 1,760 | 11 | $0.69 | $1,222 |
| 36415 Venipuncture Blood Collection | Office | 1,473 | 243 | $8.65 | $13K |
| 85025 Blood Count | Office | 1,118 | 213 | $7.60 | $8,493 |
| 99213 Office E&M - Established | Office | 982 | 196 | $73.68 | $72K |
| 99214 Office E&M - Established | Office | 498 | 112 | $105.94 | $53K |
| 96372 Injection Administration | Office | 404 | 48 | $12.33 | $4,980 |
| 96367 Intravenous Infusion, Hydration | Office | 374 | 16 | $24.74 | $9,254 |
| 96413 Chemotherapy Administration | Office | 324 | 22 | $116.40 | $38K |
| 96365 Intravenous Infusion, Hydration | Office | 280 | 45 | $55.57 | $16K |
| 96375 Injection Administration | Office | 256 | 17 | $13.40 | $3,430 |
| 96415 Chemotherapy Administration | Office | 207 | 15 | $24.59 | $5,091 |
| 99204 Office E&M - New | Office | 84 | 84 | $134.36 | $11K |
By year: 2022 $1.7M for 182,277 services; 2023 $1.5M for 170,034 services; 2024 $1.7M for 135,774 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 36415 Venipuncture Blood Collection | 1,473 | 243 | $8.65 | $13K |
| 85025 Blood Count | 1,118 | 213 | $7.60 | $8,493 |
Medicare prescription drug claims, 2024
In 2024, the drug Vijaykumar Roy prescribed most often to Medicare patients was Hydroxyurea, with 64 prescriptions and refills. In total Vijaykumar Roy wrote 700 Medicare prescriptions that cost $3.6M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Hydroxyurea Generic | 64 | 166 | 25 | $2,544 |
| Jakafi Ruxolitinib Phosphate | 50 | 50 | Under 11 | $1.3M |
| Procrit Epoetin Alfa | 46 | 46 | 13 | $190K |
| Keytruda Pembrolizumab | 36 | 36 | Under 11 | $383K |
| Privigen Immun Glob G(Igg)/Pro/Iga 0-50 | 35 | 35 | Under 11 | $161K |
| Fosaprepitant Dimeglumine Generic | 26 | 29 | Under 11 | $6,034 |
| Abiraterone Acetate Generic | 25 | 35 | Under 11 | $71K |
| Granix Tbo-Filgrastim | 23 | 23 | Under 11 | $76K |
| Dexamethasone Sodium Phosphate Generic | 23 | 26 | Under 11 | $31.24 |
| Letrozole Generic | 21 | 61 | Under 11 | $665 |
| Imatinib Mesylate Generic | 21 | 29 | Under 11 | $17K |
| Ondansetron Hcl Generic | 21 | 21 | Under 11 | $146 |
| Carboplatin Generic | 20 | 23 | Under 11 | $1,047 |
| Sprycel Dasatinib | 20 | 20 | Under 11 | $364K |
| Acyclovir Generic | 17 | 47 | Under 11 | $211 |
Brand drugs: 304 claims; generic drugs: 396 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Vijaykumar Roy $1,938 ($1,938 in general payments such as food, travel and fees) from 25 companies. The largest payer was E.R. Squibb & Sons, L.L.C. with $274.
| Company | Payments | Amount |
|---|---|---|
| E.R. Squibb & Sons, L.L.C. BMY | 14 | $274 |
| Incyte Corporation INCY | 6 | $213 |
| Seagen Inc. PFE | 2 | $183 |
| Janssen Biotech, Inc. JNJ | 9 | $151 |
| Pfizer Inc. PFE | 6 | $124 |
| Novartis Pharmaceuticals Corporation NVS | 5 | $113 |
| Genzyme Corporation SNY | 5 | $103 |
| AstraZeneca Pharmaceuticals LP AZN | 5 | $91.68 |
| Abbvie Inc. ABBV | 4 | $75.89 |
| Stemline Therapeutics Inc. | 4 | $72.57 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.